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Point-of-Care Measurement of Clopidogrel
Responsiveness Predicts Clinical Outcome in
Patients Undergoing Percutaneous Coronary Intervention
Results of the ARMYDA-PRO (Antiplatelet
therapy for Reduction of MYocardial Damage during
Angioplasty-Platelet Reactivity Predicts Outcome) Study
Giuseppe Patti, MD, FACC, Annunziata Nusca, MD, Fabio Mangiacapra, MD, Laura Gatto, MD,
Andrea D’Ambrosio, MD, Germano Di Sciascio, MD, FACC
Rome, Italy
Objectives The aim of this study was to evaluate the correlation of point-of-care measurement of platelet inhibition with
clinical outcome in patients undergoing percutaneous coronary intervention (PCI).
Background Individual variability of clopidogrel response might influence results of PCI.
Methods A total of 160 patients receiving clopidogrel before PCI were prospectively enrolled. Platelet reactivity was mea-
sured by the VerifyNow P2Y12 assay (Accumetrics Inc., San Diego, California). Primary end point was 30-day
occurrence of major adverse cardiac events (MACE) according to quartile distribution of P2Y12 reaction units
(PRU).
Results Primary end point occurred more frequently in patients with pre-procedural PRU levels in the fourth quartile
versus those in the lowest quartile (20% vs. 3%; p  0.034), and it was entirely due to periprocedural myo-
cardial infarction (MI). Mean PRU absolute levels were higher in patients with periprocedural MI (258  53
vs. 219  69 in patients without; p  0.030). On multivariable analysis pre-PCI PRU levels in the fourth
quartile were associated with 6-fold increased risk of 30-day MACE (odds ratio: 6.1; 95% confidence inter-
val: 1.1 to 18.3, p  0.033). By receiver-operating characteristic curve analysis, the optimal cut-off for the
primary end point was a pre-PCI PRU value 240 (area under the curve: 0.69; 95% confidence interval:
0.56 to 0.81, p  0.016).
Conclusions This study indicates that high pre-PCI platelet reactivity might predict 30-day events. Use of a rapid point-of-care
assay for monitoring residual platelet reactivity after clopidogrel administration might help identify patients in
whom individualized antiplatelet strategies might be indicated with coronary intervention. (J Am Coll Cardiol
2008;52:1128–33) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.06.038r
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dptimal platelet inhibition plays a key role in the prevention
f early myocardial ischemic complications during percuta-
eous coronary intervention (PCI) (1,2); accordingly, the
ssociation of aspirin and clopidogrel, a nonreversible
2Y12 platelet receptor inhibitor, represents the established
ntiplatelet therapy in this setting.
Because of inter-individual variability in clopidogrel
esponsiveness, platelet function monitoring assays are
seful tools to identify patients with different drug
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ome, Rome, Italy.c
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ccepted June 9, 2008.esponses who might potentially be at increased risk of
ecurrent cardiac events or bleeding. Adenosine diphos-
hate (ADP)-induced light transmittance aggregometry
LTA) is the standard test for evaluating platelet reac-
ivity in patients receiving clopidogrel, but this is non-
pecific and time-consuming (3); conversely, more rapid
nd specific tests measuring clopidogrel response in the
ndividual patient might be widely applicable in clinical
ractice, thereby providing risk stratification and a guide
o antithrombotic therapy. Thus, the ARMYDA study
roup (1,4 –7) has designed the ARMYDA-PRO (Anti-
latelet therapy for Reduction of MYocardial Damage
uring Angioplasty-Platelet Reactivity Predicts Out-
ome) study to prospectively evaluate whether point-of-
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utcome in patients undergoing PCI.
ethods
tudy population and design. The ARMYDA-PRO is a
rospective study including 160 patients receiving clopi-
ogrel before PCI. Patients with a variety of coronary
yndromes, including non–ST-segment elevation acute cor-
nary syndromes (ACS) were enrolled. Exclusion criteria
ere: primary PCI; platelet count70 109/l; high bleeding
isk; and severe chronic renal failure (serum creatinine 2
g/dl). All patients received 600 mg clopidogrel load approx-
mately 6 h before intervention (n  120) or were receiving
hronic clopidogrel therapy (75 mg/day for5 days, n 40).
lopidogrel was continued for 1 month after PCI and for 12
onths in patients with ACS or receiving drug-eluting
tents. All patients received aspirin.
Platelet reactivity was evaluated in the catheterization
aboratory before PCI and at 8 and 24 h after intervention
y the VerifyNow P2Y12 assay (Accumetrics Inc., San
iego, California), which is a rapid cartridge-based assay
pecifically measuring direct effects of clopidogrel on the
latelet P2Y12 receptor. Technical details were already
escribed elsewhere (8). Results are expressed as P2Y12
eaction units (PRU)—the lower the PRU value, the greater
he degree of P2Y12 receptor inhibition by clopidogrel and
ice versa. Twenty randomly selected patients were analyzed
o assess intra-assay variability, which was 2.1  1.3%
coefficient of variation: 6%).
Blood samples were also drawn before and at 8 and 24 h
n all patients for creatine kinase-myocardial band (CK-
B; mass) and troponin-I (Tn-I; mass) levels; further
easurements were obtained if symptoms suggested myo-
ardial ischemia. Measurements were performed by Access
Immunochemiluminometric assay (Beckman Coulter,
ullerton, California); normal limits were 4 ng/ml for
K-MB and 0.08 ng/ml for Tn-I. One-month and
-month clinical follow-up were obtained by office visit in
ll patients. Each patient gave informed consent to the
tudy. The study was not supported by external sources of
unding.
nd points. Primary end point of the ARMYDA-PRO
tudy was 30-day incidence of major adverse cardiac events
MACE): cardiac death, myocardial infarction (MI), target
essel revascularization, in relation to quartile distribution of
latelet reactivity measured by PRU assay. Myocardial
nfarction was defined as post-procedural increase of cardiac
iomarkers (Tn or CK-MB) 3  99th percentile of the
pper reference limit (9). Target vessel revascularization
ncluded by-pass surgery or repeat PCI of the target
essel(s).
Secondary end points were: 1) evaluation of mean PRU
bsolute values in patients with or without post-PCI
levation of markers of myocardial damage (CK-MB,
n-I); 2) distribution in PRU quartiles of patients with rny post-procedural increase of
ardiac markers above normal
imits; 3) correlation of vascular/
leeding complications to PRU
uartiles; and 4) clinical outcome
t 6-month follow-up. Bleeding
vents were defined according to
hrombolysis In Myocardial In-
arction criteria (10).
tatistics. On the basis of pa-
ients’ enrollment criteria, we as-
umed 8% overall incidence of
0-day MACE (1,11). We
ested the hypothesis that inci-
ence of 30-day MACE differed
y PRU quartiles. We assumed
s effect size for the power anal-
sis a 7-fold increased risk of
0-day MACE in patients of the
ourth quartile (12); thus, a study
opulation of at least 153 patients
ould be needed to verify this
ypothesis with alpha of 0.05 (2-tailed) and beta of 0.08.
Continuous variables were compared by t test for nor-
ally distributed values; otherwise the Mann-Whitney U
est was used. Proportions were compared by Fisher exact
est when the expected frequency was 5; otherwise the
hi-square test was applied. Event-free survival analysis was
erformed by Kaplan-Meier method with log-rank test
roup comparison. Odds ratios (ORs) and 95% confidence
ntervals (CIs) investigating the independent predictive role
f PRU quartiles on the occurrence of the primary end point
ere assessed by logistic regression. The following param-
ters were first evaluated in a univariate model: comparison
f PRU quartiles (fourth vs. first quartile, third vs. first,
econd vs. first); each of the variables indicated in Table 1;
nd procedural variables, such as stent length, direct stent-
ng, inflations duration. Only variables with p value 0.15
ere then entered into the final model of multivariable
ogistic regression analysis. Ability of the assay to discrim-
nate between patients with and without MACE at 30 days
as evaluated by receiver-operating characteristic (ROC)
urve analysis. The optimal cut-off value was calculated by
etermining the PRU value providing the greatest sum of
ensitivity and specificity. Results are expressed as mean 
D. A p value 0.05 (2-tailed) was considered significant.
nalysis was performed with SPSS 12.0 (SPSS Inc., Chi-
ago, Illinois) software.
esults
linical and procedural characteristics according to pre-
ntervention PRU quartiles are indicated in Table 1.
Procedural success was obtained in 99% of patients. No
essel or side branch (2 mm) closure occurred. No patient
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
ADP  adenosine
diphosphate
CK-MB  creatine kinase-
myocardial band
LTA  light transmittance
aggregometry
MACE  major adverse
cardiac events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
PRU  platelet (P2Y12)
reaction units
ROC  receiver-operating
characteristic
Tn  troponinequired emergency coronary artery by-pass graft.
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oint was significantly more frequent in patients with
re-procedural PRU levels in the fourth quartile versus
hose in the first quartile (20% vs. 3%; p  0.034) (Fig. 1);
his was essentially due to periprocedural MI. No further
vent occurred during 1-month follow-up.
ain Clinical and Procedural Features
Table 1 Main Clinical and Procedural Features
Variable
Total Cohort
(n  160)
First Quartile
(n  40)
Age (yrs) 66 9 65 12
Male gender 129 (81) 30 (75)
Diabetes mellitus 55 (34) 15 (38)
Hypercholesterolemia 119 (74) 32 (80)
Body mass index 25.8 3.1 25.6 3.2
Previous myocardial infarction 45 (28) 7 (18)
Previous coronary intervention 62 (39) 16 (40)
ACS/NSTEMI 87 (54) 18 (45)
Left ventricular ejection fraction (%) 56 7 56 8
Serum creatinine (mg/dl) 1.12 0.30 1.10 0.28
Statin therapy 136 (85) 35 (88)
Vessel treated
Left anterior descending 93 (49) 21 (46)
Left circumflex 43 (23) 10 (22)
Right coronary artery 52 (27.5) 15 (32)
Saphenous vein grafts 1 (0.5) —
Restenotic lesions 6 (4) 1 (3)
Lesion type B2/C 112 (70) 26 (65)
Multivessel intervention 28 (18) 6 (15)
Use of stents 149 (93) 37 (92)
Use of drug-eluting stents 41 (26) 12 (30)
Use of glycoprotein IIb/IIa inhibitors 8 (5) 3 (8)
alues are given as number of patients (%) or mean  SD.
ACS  acute coronary syndrome; NSTEMI  non–ST-segment elevation myocardial infarction.
Figure 1 The ARMYDA-PRO Study—Primary End Point
Incidence of primary end point (30-day major adverse cardiac events [MACE])
according to quartile distribution of pre-intervention platelet (P2Y12) reaction units
(PRU) values. ARMYDA-PRO  Antiplatelet therapy for Reduction of MYocardial
Damage during Angioplasty-Platelet Reactivity Predicts Outcome. Figure illustration
by Rob Flewell.yecondary end points. Higher PRU values before PCI
Fig. 2A) predicted periprocedural MI by CK-MB defi-
ition (258  53 PRU in patients with MI vs. 219  69
RU in those without MI; p  0.030) but not by Tn-I
Fig. 2B).
Likewise, any post-procedural increase of CK-MB above
pper normal limits was more frequently observed in pa-
ients in the fourth PRU quartile (48% vs. 23% in the first
uartile; p  0.035), but there was no difference in the
roportion of patients with Tn-I elevation (65% in the
ourth quartile vs. 45% in the first quartile; p  0.12).
No relationship was found between MACE and PRU
evels at 8 and 24 h after PCI (p  0.30).
No patient had major bleeding or required transfusions;
inor bleeding occurred in 9 patients (6%): 1 patient had
rethral bleeding from a Foley catheter and 8 had small
ntry-site hematomas, independent of baseline PRU quar-
iles. There were no side-effects in either group requiring
iscontinuation of clopidogrel. At 6-month follow-up, the
umulative incidence of MACE was 10% in the first
uartile, 13% in the second, 17% in the third, and 30% in
he fourth quartile (p  0.05 first vs. fourth quartile).
ultivariable analysis. Whereas the comparison of third
nd second quartiles versus first was not different (p  0.68
nd p  0.71, respectively), multivariable analysis revealed
hat pre-PCI PRU levels in the fourth quartile were
ndependent predictors of higher risk of adverse events at 30
ays (OR: 6.1; 95% CI: 1.1 to 18.3; p  0.033). Age 70
Second Quartile
(n  40)
Third Quartile
(n  40)
Fourth Quartile
(n  40) p Value
66 10 67 8 68 10 0.58
32 (80) 29 (73) 38 (95) 0.07
11 (28) 15 (38) 14 (35) 1.00
26 (65) 32 (80) 29 (73) 0.48
26.2 3.4 26 3.1 25.7 3.2 0.83
12 (30) 13 (33) 13 (33) 0.52
18 (45) 14 (35) 14 (35) 1.00
27 (67) 22 (55) 20 (50) 0.28
55 8 55 6 56 8 0.87
1.09 0.21 1.14 0.21 1.16 0.35 0.61
36 (90) 34 (85) 31 (78) 0.59
24 (52) 26 (52) 22 (47) 0.93
11(24) 11 (22) 11 (23) 1.00
11 (24) 12 (24) 14 (30) 0.98
— 1 (2) — —
1 (3) 3 (8) 1 (3) 0.76
28 (70) 31 (78) 27 (67) 0.88
5 (13) 10 (25) 7 (18) 0.67
37 (92) 38 (95) 37 (92) 1.00
11 (28) 11 (28) 7 (18) 0.80
2 (5) 1 (3) 2 (5) 1.00ears, left ventricular dysfunction, and use of glycoprotein
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September 30, 2008:1128–33 Clopidogrel Response and Outcome After PCIIb/IIIa inhibitors were also associated with increased risk,
hereas statin therapy at the time of PCI had a protective
ffect (OR: 0.21; CI: 0.10 to 0.91; p  0.037) (4,7).
OC curve analysis. The ROC curve analysis showed that
RU levels significantly discriminate between patients with
nd without 30-day MACE with an area under the curve of
.69 (95% CI: 0.56 to 0.81; p 0.016). A PRU value240
as identified as the optimal cutoff point to predict 30-day
utcome, with sensitivity of 81% and specificity of 53%.
iscussion
his prospective study indicates that high residual plate-
et reactivity after clopidogrel administration, measured
y a point-of-care assay at the time of intervention, is
ssociated with higher incidence of 30-day MACE after
CI; this outcome is mainly driven by increased risk of
eriprocedural MI.
Evaluation of individual clopidogrel responsiveness is an
merging issue in interventional cardiology. Wide variability
s reported (13), ascribed in turn to differences in drug
bsorption, variations in biotransformation rate into active
etabolite (due to drug–drug interactions at the site of
ytochrome P or genetic CYP3A polymorphisms) (14),
2Y12 receptor polymorphisms affecting receptor number
nd activity (15), and even noncompliance (16). The prev-
lence of reduced clopidogrel responsiveness varies from
% to 30% (2,13,17), depending on the assay used,
efinitions empirically applied, and presence of potential
onfounders.
Several methods have been used to evaluate clopidogrel
esponse in patients undergoing PCI, with the aim of
dentifying those at higher risk of adverse events (18), with
ptical aggregometry after ADP stimulation being the most
idely used in previous studies. A low platelet response to
Figure 2 The ARMYDA-PRO Study—Secondary End Points
Distribution of pre-intervention PRU levels according to post–percutaneous coronar
creatine kinase-myocardial band (CK-MB) (A) and troponin-I (Tn-I) (B) values. Abbrelopidogrel measured with LTA was associated with in- ireased incidence of periprocedural myocardial injury (19),
ardiovascular events at short- (12,20) and midterm (2,21),
nd stent thrombosis (22). Nevertheless, this test has a
umber of limitations, such as need for highly trained
ersonnel, repeated centrifugations, large sample volume,
ength of assay time, and suboptimal reproducibility (3).
urthermore, it is nonspecific, because it also measures
ggregation due to binding of ADP to P2Y1 platelet
eceptor, which is not inhibited by clopidogrel.
Vasodilator-stimulated phosphoprotein phosphorylation
y flow cytometry is more specific, because it directly
easures effects of the drug on the target receptor; in
bservational studies, a lower platelet inhibition assessed by
asodilatator-stimulated phosphoprotein was observed in
atients with stent thrombosis (22). Cost and need for long
ample preparation and skilled personnel limit a widespread
se of this test (3).
Platelet reactivity by VerifyNow can be rapidly measured
ithout sample preparation by moderately experienced per-
onnel with low sample volumes; the test specifically reflects
he extent of ADP-induced inhibition of adenylyl cyclase,
hich is mediated uniquely by action of clopidogrel on the
2Y12 receptor. The assay allows detection of absolute
RU values and percent P2Y12 receptor inhibition, which
ight be calculated as a percent change from baseline
latelet aggregation (8,23). A close correlation was de-
cribed between results of ADP-induced optical aggre-
ometry and absolute PRU values by VerifyNow assay in
atients undergoing PCI (24). This method was also
ested and clinically validated in a multicenter prospective
tudy (VERITAS [VERIfy Thrombosis risk Assess-
ent]) (23).
In this study we demonstrate the correlation between
lopidogrel response and clinical outcome after coronary
vention
ns as in Figure 1. Figure illustration by Rob Flewell.y inter
viationtervention. Although multivariable analysis might be
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luded, the predictive value for adverse events of the
ourth quartile of platelet reactivity was independent of
ossible confounding factors, with a 6-fold increased risk
f periprocedural MI versus the first quartile. An ROC
nalysis indicated that this assay can predict outcome at
0 days, with optimal cutoff point to discriminate pa-
ients at higher risk of events of 240 PRU, and a
ositive predictive value of 81%. The threshold identified
n our study coincides with that observed by Price et al.
25) in an observational study in which a cutoff 235
RU correlated with 6-month events, including stent
hrombosis, in patients receiving sirolimus-eluting stents.
n ARMYDA-PRO, the negative predictive value of
RU in the first quartile was 98%, with minimal proba-
ility of early adverse events with PRU levels 178.
nterestingly, higher PRU values correlated with CK-MB
levation but not with Tn-I elevation, suggesting that
latelet-unrelated events (i.e., distal embolization) might
e also responsible for Tn raise after PCI (12). No cut-off
alue for events was described in a recent study (26) on
table patients treated with drug-eluting stents after
ariable loading doses of clopidogrel (300 or 600 mg) that
lso used VerifyNow.
We used quartile distribution, because clopidogrel re-
ponsiveness is multifactorial and it should be considered as
continuum; accordingly, a progressively increasing inci-
ence of events was observed across PRU quartiles (Fig. 1),
ith a similar pattern of correlation between PRU values
nd peak levels of myocardial markers (Fig. 2).
Unlike the Price et al. study (25), ARMYDA-PRO was
ot powered to evaluate relationship between degree of
lopidogrel inhibition and occurrence of bleeding compli-
ations or late thrombotic events; larger prospective studies
ith longer follow-up are needed to address this issue.
Clopidogrel responsiveness variability, within the en-
anced thrombotic milieu of PCI, requires careful evalua-
ion. The ARMYDA-PRO study supports the use of a
apid point-of-care assay for monitoring residual platelet
eactivity after clopidogrel administration: VerifyNow can
e a useful and easily applicable method that might help
stablish a clinically driven threshold of platelet reactivity
hat would identify patients at higher risk of periprocedural
vents; in those, individualized antithrombotic strategies
i.e., restricted use of drug-eluting stents, more extensive use
f glycoprotein IIb/IIIa inhibitors, higher clopidogrel main-
enance dose, or use of newer P2Y12 receptor antagonists)
ight be indicated to improve clinical outcome after coro-
ary intervention.
eprint requests and correspondence: Prof. Germano Di Scias-
io, Department of Cardiovascular Sciences, Campus Bio-Medico
niversity, Via Alvaro del Portillo, 200, 00128 Rome, Italy.
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